

### This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
<b>Cancer</b>				
Cancer	Mitogen-activated protein kinase 7 (MAPK7; BMK1; ERK-5)	A study in rodents identified a BMK1 inhibitor that could help treat cancer. In a panel of human cancer cell lines, the BMK1-specific inhibitor XMD8-92 lowered proliferation compared with no treatment. In mice, XMD8-92 decreased tumor growth compared with vehicle control ( $p < 0.01$ ). Next steps could include developing an optimized BMK1 inhibitor and evaluating the compound in preclinical cancer models.	Patented for use in oncology; available for licensing from the Dana-Farber Cancer Institute Office of Research and Technology Ventures	Yang, Q. <i>et al. Cancer Cell</i> ; published online Sept. 14, 2010; doi:10.1016/j.ccr.2010.08.008 <b>Contact:</b> Jiing-Dwan Lee, The Scripps Research Institute, La Jolla, Calif. e-mail: <a href="mailto:jdlee@scripps.edu">jdlee@scripps.edu</a>
		<b>SciBX 3(38); doi:10.1038/scibx.2010.1146</b> Published online Sept. 30, 2010		